Treatment of risdiplam after nusinersen continuously improves upper limb motor function in spinal muscular atrophy patients: a multicenter experience
Despite the small sample size and lack of a control group, these findings suggest that switching from nusinersen to risdiplam in real-world clinical settings is safe and allows for continued improvement of motor function in SMA patients.
Authors
- Liqiang Yu (ORCID: https://orcid.org/0000-0001-6132-2124)
- Liang-Hua Zhu
- Han-Bing Lu
- Qi Niu (ORCID: https://orcid.org/0000-0001-9237-9553)
- Xi Cheng (ORCID: https://orcid.org/0000-0001-9522-7352)
- Ya-Bei Fan
- Yun Ma
Institutions
- Soochow University (TW)
- Soochow University (CN)
- Xuzhou Central Hospital (CN)
- Jiangsu Province Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fped.2026.1679549
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Nanjing Medical University